Docoh
Loading...

ZYNE Zynerba Pharmaceuticals

Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Zynerba Pharmaceuticals is committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies.

Company profile

Ticker
ZYNE
Exchange
Website
CEO
Armando Anido
Employees
Incorporated
Location
Fiscal year end
Former names
Zynerba Pharmeceuticals, Inc.
SEC CIK
Subsidiaries
Zynerba Pharmaceuticals Pty Ltd ...

ZYNE stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

9 Aug 21
28 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 85.78M 85.78M 85.78M 85.78M 85.78M 85.78M
Cash burn (monthly) 2.45M (positive/no burn) 3.28M 3.1M 2.43M 2.94M
Cash used (since last report) 9.65M n/a 12.92M 12.19M 9.56M 11.57M
Cash remaining 76.13M n/a 72.86M 73.59M 76.22M 74.22M
Runway (months of cash) 31.1 n/a 22.2 23.8 31.4 25.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
3 Aug 21 Moch Kenneth I Common Stock Grant Acquire A No No 0 5,000 0 5,000
3 Aug 21 Moch Kenneth I Stock Option Common Stock Grant Acquire A No No 4.44 7,500 33.3K 7,500
3 Aug 21 Cooper Warren D Common Stock Grant Acquire A No No 0 5,000 0 5,000
3 Aug 21 Cooper Warren D Stock Option Common Stock Grant Acquire A No No 4.44 7,500 33.3K 7,500
3 Aug 21 Federici William J Common Stock Grant Acquire A No No 0 5,000 0 5,000
3 Aug 21 Federici William J Stock Option Common Stock Grant Acquire A No No 4.44 7,500 33.3K 7,500
3 Aug 21 Kisner Daniel L Common Stock Grant Acquire A No No 0 5,000 0 5,000
3 Aug 21 Kisner Daniel L Stock Option Common Stock Grant Acquire A No No 4.44 7,500 33.3K 7,500
3 Aug 21 John P. Butler Common Stock Grant Acquire A No No 0 5,000 0 10,000
3 Aug 21 John P. Butler Stock Option Common Stock Grant Acquire A No No 4.44 7,500 33.3K 7,500

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

37.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 67 68 -1.5%
Opened positions 11 19 -42.1%
Closed positions 12 10 +20.0%
Increased positions 24 20 +20.0%
Reduced positions 16 11 +45.5%
13F shares
Current Prev Q Change
Total value 78.16M 43.76M +78.6%
Total shares 15.4M 9.8M +57.2%
Total puts 289.9K 530.5K -45.4%
Total calls 556.3K 803.8K -30.8%
Total put/call ratio 0.5 0.7 -21.0%
Largest owners
Shares Value Change
Etf Managers 4.58M $24.82M +130.4%
Vanguard 1.88M $9.92M +70.1%
Mirae Asset Global Investments 1.64M $8.67M +457.6%
D. E. Shaw & Co. 1.07M $5.68M +249.5%
Davy Global Fund Management 962.63K $5.09M +33.4%
BLK Blackrock 774.26K $4.1M +30.1%
Genesis Capital Advisors 749.64K $0 0.0%
Millennium Management 388.45K $2.06M +1635.7%
Penserra Capital Management 372.38K $1.97M +4.3%
Geode Capital Management 323.11K $1.71M +35.2%
Largest transactions
Shares Bought/sold Change
Etf Managers 4.58M +2.59M +130.4%
Mirae Asset Global Investments 1.64M +1.34M +457.6%
AdvisorShares Investments 273.4K -1.26M -82.2%
Vanguard 1.88M +773.34K +70.1%
D. E. Shaw & Co. 1.07M +765.96K +249.5%
Millennium Management 388.45K +366.07K +1635.7%
Davy Global Fund Management 962.63K +241.05K +33.4%
MS Morgan Stanley 277.69K +208.8K +303.1%
BLK Blackrock 774.26K +179.24K +30.1%
PDT Partners 151.96K +151.96K NEW
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: carrier, deposited, dismissed, escrow, evidence, fault, hearing, imputed, institute, prioritizing, scheduled, SM, Stipulation
Removed: adjustment, beginning, investigator, NaN, prior, satisfaction, shipment, speaking, statement, supplement

Patents

APP
Utility
Treatment of SYNGAP1 Encephalopathy
18 Mar 21
The present technology relates to methods of treating SYNGAP1 encephalopathy by transdermally administering an effective amount of cannabidiol (CBD) to the subject, wherein a SYNGAP1 symptom is treated in the subject.
APP
Utility
Prodrugs of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same
18 Feb 21
Described herein are Δ9-THC prodrugs, methods of making Δ9-THC prodrugs, formulations comprising Δ9-THC prodrugs and methods of using Δ9-THC.
APP
Utility
Synthetic Transdermal Cannabidiol for the Treatment of Focal Epilepsy In Adults
4 Feb 21
The present technology relates to a method of reducing seizure frequency in a subject having epilepsy by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein the seizure frequency is reduced.
APP
Utility
Treatment of Fragile X Sydrome with Cannabidiol
18 Nov 20
The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.
GRANT
Utility
Treatment of fragile x syndrome with cannabidiol
31 Aug 20
The present technology relates to a method of treating one or more behavioral symptoms of Fragile X Syndrome in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of Fragile X Syndrome are treated in the subject.